Drug Profile
Triflusal - Simcere
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antiplatelets; Salicylates
- Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Cerebrovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cardiovascular-disorders in China
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cerebrovascular-disorders in China
- 06 Jul 2011 Phase-I clinical trials in Cardiovascular disorders in China (unspecified route)